T1	Form 90 95	crema
T2	CHEM 99 109	rapamicina
#1	AnnotatorNotes T2	C0072980; sirolimus; Antibiotic · Organic Chemical
T3	PROC 110 130	aplicada tópicamente
T4	Route 119 130	tópicamente
T5	LIVB 133 142	pacientes
#2	AnnotatorNotes T5	C0030705; Patients; Patient or Disabled Group
T6	PROC 143 157	diagnosticados
#3	AnnotatorNotes T6	C0011900; Diagnosis; Diagnostic Procedure
T7	DISO 162 187	manchas en vino de Oporto
#4	AnnotatorNotes T7	C0235752; Port-Wine Stain; Congenital Abnormality
T8	CHEM 251 261	rapamicina
#5	AnnotatorNotes T8	C0072980; sirolimus; Antibiotic · Organic Chemical
T9	PROC 263 417	Estudio preliminar de la eficacia (dosis-respuesta) de fase II, con enmascaramiento doble, comparativo con un placebo, aleatorizado y con grupos paralelos
T10	Form 489 494	crema
T11	CHEM 498 508	rapamicina
#6	AnnotatorNotes T11	C0072980; sirolimus; Antibiotic · Organic Chemical
T12	PROC 509 529	aplicada tópicamente
T13	Route 518 529	tópicamente
T14	LIVB 532 541	pacientes
#7	AnnotatorNotes T14	C0030705; Patients; Patient or Disabled Group
T15	PROC 542 556	diagnosticados
#8	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 561 586	manchas en vino de Oporto
#9	AnnotatorNotes T16	C0235752; Port-Wine Stain; Congenital Abnormality
T17	LIVB 608 617	Pacientes
#10	AnnotatorNotes T17	C0030705; Patients; Patient or Disabled Group
T18	PROC 618 632	diagnosticados
#11	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 637 662	manchas en vino de Oporto
#12	AnnotatorNotes T19	C0235752; Port-Wine Stain; Congenital Abnormality
T20	LIVB 742 766	Pacientes de ambos sexos
T21	Age 770 789	≥3 meses y ≤18 años
T22	PROC 826 850	consentimiento informado
#13	AnnotatorNotes T22	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T23	LIVB 856 865	Pacientes
#14	AnnotatorNotes T23	C0030705; Patients; Patient or Disabled Group
T24	DISO 880 905	manchas en vino de Oporto
#15	AnnotatorNotes T24	C0235752; Port-Wine Stain; Congenital Abnormality
T25	ANAT 912 916	cara
#16	AnnotatorNotes T25	C0015450; Face; Body Location or Region | C1281591; Entire face; Body Location or Region
T26	ANAT 921 927	cuello
#17	AnnotatorNotes T26	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C0027530; Neck; Body Location or Region | C1281592; Entire neck; Body Part, Organ, or Organ Component
T27	ANAT 932 938	tronco
#18	AnnotatorNotes T27	C0460005; Trunk structure; Body Location or Region | C1280632; Entire trunk; Body Part, Organ, or Organ Component
T28	ANAT 945 951	brazos
#19	AnnotatorNotes T28	C0446516; Upper arm; Body Location or Region | C1140618; Upper Extremity; Body Part, Organ, or Organ Component | C1269612; Entire upper arm; Body Part, Organ, or Organ Component
T29	DISO 971 996	manchas en vino de Oporto
#20	AnnotatorNotes T29	C0235752; Port-Wine Stain; Congenital Abnormality
T30	LIVB 1063 1072	pacientes
#21	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 1080 1102	representantes legales
T32	PHYS 1119 1129	comprender
T33	PROC 1149 1164	estudio clínico
#22	AnnotatorNotes T33	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T34	PROC 1184 1220	consentimiento informado por escrito
T35	LIVB 1252 1261	pacientes
#23	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 1269 1291	representantes legales
T37	LIVB 1327 1335	paciente
#24	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	PROC 1350 1363	instrucciones
#25	AnnotatorNotes T38	C0220931; Training; Educational Activity
T39	LIVB 1368 1380	investigador
#26	AnnotatorNotes T39	C0035173; Research Personnel; Professional or Occupational Group
T40	LIVB 1387 1411	investigador colaborador
T41	LIVB 1421 1430	pacientes
#27	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Form 1498 1503	crema
T43	ANAT 1570 1574	piel
#28	AnnotatorNotes T43	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T44	LIVB 1652 1661	Pacientes
#29	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	PROC 1690 1701	tratamiento
#30	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	DISO 1705 1708	LCP
#31	AnnotatorNotes T46	C0023484; Leukemia, Plasma Cell; Neoplastic Process
T47	PROC 1724 1735	tratamiento
#32	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	ANAT 1773 1777	piel
#33	AnnotatorNotes T48	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T49	LIVB 1843 1852	Pacientes
#34	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	DISO 1857 1860	MVO
T51	ANAT 1868 1889	extremidades distales
T52	ANAT 1901 1913	partes acras
T53	LIVB 1918 1927	Pacientes
#35	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Neg_cue 1954 1956	no
T55	PROC 1974 1990	plan terapéutico
T56	PROC 2006 2033	evaluaciones de seguimiento
T57	Negated 2006 2033	evaluaciones de seguimiento
T58	LIVB 2039 2048	Pacientes
#36	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	DISO 2053 2070	lesiones cutáneas
#37	AnnotatorNotes T59	C0037284; Skin lesion; Disease or Syndrome | C3241942; Sore on skin; Finding
T60	DISO 2084 2093	erosiones
#38	AnnotatorNotes T60	C0015256; Excoriation; Injury or Poisoning | C0040436; Tooth Erosion; Disease or Syndrome | C0333307; Superficial ulcer; Acquired Abnormality | C3887524; Skin Erosion; Disease or Syndrome
T61	DISO 2096 2103	úlceras
#39	AnnotatorNotes T61	C0041582; Ulcer; Pathologic Function
T62	LIVB 2109 2118	Pacientes
#40	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	DISO 2123 2140	hipersensibilidad
#41	AnnotatorNotes T63	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T64	LIVB 2203 2212	Pacientes
#42	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T65	PROC 2232 2253	tratamiento sistémico
T66	CHEM 2258 2268	rapamicina
#43	AnnotatorNotes T66	C0072980; sirolimus; Antibiotic · Organic Chemical
T67	CHEM 2269 2278	sirólimus
#44	AnnotatorNotes T67	C0072980; sirolimus; Antibiotic · Organic Chemical
T68	CHEM 2280 2290	everólimus
#45	AnnotatorNotes T68	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T69	CHEM 2293 2305	temsirólimus
#46	AnnotatorNotes T69	C1707080; temsirolimus; Organic Chemical · Pharmacologic Substance
T70	Duration 2326 2337	los 3 meses
T71	PROC 2352 2365	reclutamiento
#47	AnnotatorNotes T71	C0242800; Patient Recruitment; Research Activity
T72	LIVB 2371 2380	Pacientes
#48	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	PROC 2400 2421	tratamiento con láser
T74	PROC 2448 2471	intervención quirúrgica
#49	AnnotatorNotes T74	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T75	PROC 2477 2483	tratar
T76	DISO 2487 2511	mancha en vino de Oporto
#50	AnnotatorNotes T76	C0235752; Port-Wine Stain; Congenital Abnormality
T77	Duration 2532 2543	los 3 meses
T78	PROC 2558 2571	reclutamiento
#51	AnnotatorNotes T78	C0242800; Patient Recruitment; Research Activity
T79	LIVB 2591 2600	Pacientes
#52	AnnotatorNotes T79	C0030705; Patients; Patient or Disabled Group
T80	PROC 2631 2646	estudio clínico
#53	AnnotatorNotes T80	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T81	Duration 2667 2678	los 3 meses
T82	PROC 2700 2713	reclutamiento
#54	AnnotatorNotes T82	C0242800; Patient Recruitment; Research Activity
T83	LIVB 2719 2728	Pacientes
#55	AnnotatorNotes T83	C0030705; Patients; Patient or Disabled Group
T84	LIVB 2736 2748	investigador
#56	AnnotatorNotes T84	C0035173; Research Personnel; Professional or Occupational Group
T85	LIVB 2754 2778	investigador colaborador
T86	PROC 2833 2848	estudio clínico
#57	AnnotatorNotes T86	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T87	LIVB 2907 2914	Mujeres
#58	AnnotatorNotes T87	C0043210; Woman; Population Group | C0242665; wife; Family Group
T88	Neg_cue 2980 2982	no
T89	PROC 2992 3015	métodos anticonceptivos
#59	AnnotatorNotes T89	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T90	Negated 2992 3015	métodos anticonceptivos
T91	LIVB 3029 3036	varones
T92	Neg_cue 3061 3063	no
T93	PROC 3073 3096	métodos anticonceptivos
#60	AnnotatorNotes T93	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T94	Negated 3073 3096	métodos anticonceptivos
T95	LIVB 3113 3122	Pacientes
#61	AnnotatorNotes T95	C0030705; Patients; Patient or Disabled Group
T96	DISO 3127 3161	disfunción del sistema inmunitario
T97	PROC 3194 3220	tratamiento inmunodepresor
T98	PROC 44 83	Estudio de eficacia y búsqueda de dosis
T99	PROC 208 247	Estudio de eficacia y búsqueda de dosis
T100	DISO 687 712	Manchas en vino de Oporto
T101	PROC 1485 1503	aplicarse la crema
T102	DISO 1529 1553	mancha en vino de Oporto
T103	PROC 1628 1646	escala Fitzpatrick
T104	PROC 1819 1837	escala Fitzpatrick
T105	Negated 1974 1990	plan terapéutico
T106	PROC 1300 1322	cumplimentar el diario
T107	LIVB 2855 2874	Mujeres embarazadas
T108	PHYS 2891 2900	lactancia
T109	CHEM 2161 2185	componentes del producto
T110	Spec_cue 2919 2925	puedan
T111	PHYS 2935 2946	embarazadas
T112	Speculated 2935 2946	embarazadas
T113	Route 2244 2253	sistémico
T114	Food 698 712	vino de Oporto
T115	Result_or_Value 1000 1015	al menos 36 cm2
T116	Result_or_Value 1032 1052	al menos 6 cm x 6 cm
T117	Observation 1232 1242	participar
T118	Observation 1437 1447	dispuestos
T119	Quantifier_or_Qualifier 1600 1621	tipos I, II, III o IV
T120	CONC 1628 1646	escala Fitzpatrick
T121	Result_or_Value 1800 1812	tipos V o VI
T122	CONC 1819 1837	escala Fitzpatrick
T123	Observation 1941 1951	dispuestos
T124	Quantifier_or_Qualifier 2071 2077	graves
T125	Observation 2605 2646	hayan participado en otro estudio clínico
T126	Observation 2801 2848	idóneos para participar en este estudio clínico
T127	Observation 2958 2977	sexualmente activas
T128	Quantifier_or_Qualifier 3016 3025	adecuados
T129	Observation 3037 3056	sexualmente activos
T130	Quantifier_or_Qualifier 3097 3106	adecuados
T131	Patient 133 142	pacientes
T132	Patient 532 541	pacientes
T133	Patient 608 617	Pacientes
T134	Patient 742 766	Pacientes de ambos sexos
T135	Patient 856 865	Pacientes
T136	Patient 1063 1072	pacientes
T137	Other 1080 1102	representantes legales
T138	Patient 1252 1261	pacientes
T139	Other 1269 1291	representantes legales
T140	Patient 1327 1335	paciente
T141	Other 1368 1380	investigador
T142	Other 1387 1411	investigador colaborador
T143	Patient 1421 1430	pacientes
T144	Patient 1652 1661	Pacientes
T145	Patient 1843 1852	Pacientes
T146	Patient 1918 1927	Pacientes
T147	Patient 2039 2048	Pacientes
T148	Patient 2109 2118	Pacientes
T149	History_of 2123 2140	hipersensibilidad
T150	Patient 2203 2212	Pacientes
T151	History_of 2232 2253	tratamiento sistémico
T152	History_of 2258 2268	rapamicina
T153	History_of 2269 2278	sirólimus
T154	History_of 2280 2290	everólimus
T155	History_of 2293 2305	temsirólimus
T156	Patient 2371 2380	Pacientes
T157	History_of 2400 2421	tratamiento con láser
T158	History_of 2448 2471	intervención quirúrgica
T159	Patient 2591 2600	Pacientes
T160	History_of 2631 2646	estudio clínico
T161	Patient 2719 2728	Pacientes
T162	Other 2736 2748	investigador
T163	Other 2754 2778	investigador colaborador
T164	Patient 2855 2900	Mujeres embarazadas o en período de lactancia
T165	Patient 2907 2914	Mujeres
T166	Patient 3029 3036	varones
T167	Patient 3113 3122	Pacientes
